Response Biomedical Announces Launch of RAMP Dengue Test for Mosquitoes Carrying Zika Virus (among others)Friday, February 19, 2016
Vancouver, BC, February 19, 2016--(T-Net)--Response Biomedical Corp. (RBM.TO)(RPBIF) announced today that it has launched the RAMP® Dengue Environmental test at the American Mosquito Control Association (AMCA) annual general meeting in Savannah, Georgia.
The RAMP® Dengue test is a rapid, quantitative test for detection of Dengue antigen in mosquitoes that transmit Dengue virus, a member of the Flavivirus genus that includes West Nile Virus, Zika Virus, Yellow Fever Virus and Japanese Encephalitis Virus.
The RAMP® Dengue test can detect the presence of all four strains of the Dengue virus in mosquitoes.
Data presented at the AMCA meeting indicated the test is highly sensitive and specific for the detection of Dengue antigen. In an independent evaluation of the technology, the Centers for Disease Control and Prevention (CDC) presented data showing the RAMP® Dengue test could detect a single positive infected mosquito in a pool of 25 for each of the four types of the Dengue virus, gave no false positives with non-infected mosquitoes and did not cross-react with other Flaviviruses (unpublished data).
The RAMP® Dengue test is the first quantitative, protein-based detection assay available for mosquito surveillance agencies and health departments to detect the presence of this deadly virus. The Dengue test, along with a similar RAMP® Environmental test for West Nile Virus, is available worldwide and sold in the United States, Latin America and the Middle East by ADAPCO, a member of the Azelis Americas group of companies.
Steve Burt, President of ADAPCO said "RAMP®Environmental tests bring reassurance to those who feel threatened by these diseases and provide an actionable early warning system to government and regional agencies. This is the first line of defense against these emerging threats and we are pleased to offer our customers a solution to enhance their mosquito control efforts and public health campaigns." ADAPCO is the world's largest distributor of innovative products for the professional mosquito control industry and has marketed the RAMP® West Nile Virus test to be the number one antigen detection system in North America.
"The expansion of the RAMP® Environmental line to include a rapid test for Dengue strengthens the position of Response as an expert in the detection of life-threatening viruses that use mosquitoes as their mode of transmission," said Dr. Barbara Kinnaird, Chief Executive Officer of Response. "This new test allows Response to expand its environmental testing sales into the Southern Hemisphere and new territories where mosquito borne Dengue virus is becoming an increased threat," noted Dr. Kinnaird.
Dengue virus is a global concern, infecting an estimated 400 million people each year in over 100 countries, resulting in approximately 100 million cases of Dengue fever, a severe flu-like illness1. Complications from the disease result in approximately 20,000 deaths each year and are a leading cause of hospitalization and death in tropical areas1,2. A recent outbreak in Hawaii has affected 254 people, prompting the Hawaii Department of Health to issue a notice3. While development efforts are ongoing, there is currently no vaccine to protect against the Dengue virus and there is no specific treatment for Dengue fever. Control of vector mosquito populations is currently the only means of preventing the spread of Dengue1.
About Response Biomedical Corp.
Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP®platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, bacterial sepsis, thromboembolism, influenza A and B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and Dengue Fever antigen and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
ADAPCO is the world's largest distributor to the professional mosquito control industry, with a vast line of products from over 25 well respected manufacturers. ADAPCO takes pride in partnering with suppliers that are dedicated to improving the mosquito control industry through research and new product development, resulting in a wide range of the best quality products available for mosquito control. For further information, please visit the Company's website at www.myadapco.com.
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about Response Biomedical Corp. Examples of forward-looking statements in this press release include statements regarding our belief that RAMP® Environmental tests bring reassurance to those who feel threatened by these diseases and provide an actionable early warning system to government and regional agencies, that the expansion of the RAMP® Environmental line to include a rapid test for Dengue strengthens the position of Response as an expert in the detection of life-threatening viruses that use mosquitoes as their mode of transmission and that this new test allows Response to expand its environmental testing sales into the Southern Hemisphere and new territories where mosquito borne Dengue virus is becoming an increased threat. These statements are only predictions based on our current expectations and projections about future events. Although we believe the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct and if such expectations are not met, our business may suffer.
Readers should not place undue reliance on these statements. Actual events or results may differ materially. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many factors may cause the Company's actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual report on Form 10-K, our quarterly reports on Form 10-Q, our Current Reports on Form 8-K, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities.
The forward-looking statements contained in this news release are current as of the date hereof and are qualified in their entirety by this cautionary statement. Except as expressly required by applicable securities laws, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
1 "Dengue and severe dengue Fact sheet No117". WHO. May 2015.
Retrieved from http://www.who.int/mediacentre/factsheets/fs117/en/ 11 February 2016
2 Gubler DJ (July 1998)."Dengue and dengue hemorrhagic fever". Clin. Microbiol. Rev. 11 (3): 480-96.
3 "Dengue Fever - Hawaii Island Outbreak". Hawaii Department of Health, 11 February 2016.
Retrieved from http://health.hawaii.gov/docd/dengue-outbreak-2015/ 11 February 2016
Burnaby (Biotech/Life Sciences)
Response Biomedical Corporation
Copyright © T-NET. All Rights Reserved. | http://www.bctechnology.com
buy viagra pill online
cheap viagra india
cheap herbal viagra
cheap pill viagra
buy levitra viagra online
buy viagra cialis levitra
cheap pharmaceutical viagra
buy viagra online and get prescription
buy viagra online online pharmacy
buy say viagra
buy line viagra
buy female viagra
buy line viagra where
cialis overnight shipping
purchase viagra online
buy generic viagra usa